Speech-Language Pathologists in Aliquippa, PA Accepting Medicare

15 Speech-Language Pathologists found. Showing 1 - 15

Mrs. Faye S. Brockmiller, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5207 Glenwall Dr, Aliquippa, PA 15001 Phone: 724-378-1907

Mrs. Katie Marie Scott, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 616 Golf Course Rd, Aliquippa, PA 15001 Phone: 724-375-0345

Ellora Francica Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd Ste A, Aliquippa, PA 15001 Phone: 724-888-2548

Lindsay Barry, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd, Suite A, Aliquippa, PA 15001 Phone: 724-888-2548

Mrs. Debra Ann Wygant, M.A, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 Pleasant Dr, Aliquippa, PA 15001 Phone: 412-760-0542

Reach For Speech Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd, Suite A, Aliquippa, PA 15001 Phone: 724-888-2548    Fax: 724-888-2913

Lauren Vorbach, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd Ste A, Aliquippa, PA 15001 Phone: 724-888-2548    Fax: 724-888-2913

Mrs. Kimberly Ann Morgan, MA CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 616 Golf Course Rd, Aliquippa, PA 15001 Phone: 724-375-0345    Fax: 724-375-1084

Amelia Christianne Spangler Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 616 Golf Course Rd, Aliquippa, PA 15001 Phone: 724-375-0345

Lauren Alexandra Moyer, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd Ste A, Aliquippa, PA 15001 Phone: 724-888-2548

Meredith Elise Mcwilliams, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd Ste A, Aliquippa, PA 15001 Phone: 724-888-2548

Kasey Chapla Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 5633 Alan St, Aliquippa, PA 15001 Phone: 412-389-9005

Danielle Jo Catena, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd Ste A, Aliquippa, PA 15001 Phone: 724-888-2548

Hannah Rogan Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3399 Brodhead Rd, Aliquippa, PA 15001 Phone: 254-872-4888

Brittany Rosati, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 Bainbridge Dr, Aliquippa, PA 15001 Phone: 724-561-5357

News Archive

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

First mammogram - what women want!

Women in their 40s considering their first screening mammogram want information on potential harm and benefits and want to participate in the decision-making process, according to a study in the June 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

Glaucoma likely to end in visual impairment

Visual impairment at the end of life is highly likely to occur in patients with glaucoma, show Dutch study results.

Start of clinical validation study of Down's syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

Read more Medical News

› Verified 2 days ago